Continuing Disclosure and Knowledge Transfer. No later than [**] Business Days prior to the scheduled date for each Scheduled JSC meeting during the Collaboration Period and thereafter during the Exclusivity Period as reasonably agreed by the Parties, Spark shall provide to Pfizer a written summary of Spark Know-How that is developed by Spark or that otherwise comes into the Control of Spark during the preceding reporting period to the extent such Know-How has not otherwise been disclosed to Pfizer (e.g., through inclusion in information provided to Pfizer via the JSC), is covered by the license granted to Pfizer under Section 2.1 and Section 2.2 and is necessary or useful for the Development, Manufacture, Commercialization or use of Compounds or Licensed Products in the Field. During the Term, subject to Section 4.15, Spark shall make appropriate personnel available to Pfizer at reasonable times, places and frequency and upon reasonable prior notice for the purpose of assisting Pfizer to understand and use the Spark Technology in connection with Pfizer’s Development, Manufacture, Commercialization and use of Compounds and Licensed Products.
Continuing Disclosure and Knowledge Transfer. On a [ * ] basis, or more frequently at the reasonable request of Pfizer during the Term, Sangamo, to the extent not previously provided to Pfizer, will provide to Pfizer a written summary of all Licensed Technology other than Research Program Technology developed by Sangamo or that otherwise comes into the Control of Sangamo. Further, Sangamo will make appropriate personnel available to Pfizer at reasonable times and places and upon reasonable prior notice for the purpose of assisting Pfizer to understand and use the Licensed Technology in connection with Pfizer’s Development of Compounds and Products.
Continuing Disclosure and Knowledge Transfer. On a Calendar Quarter basis, or more frequently at the reasonable request of AMAG during the Term, Palatin shall disclose to AMAG any Palatin Know-How developed by Palatin since Palatin’s most recent disclosure. Such disclosure shall be in either the format in which such Palatin Know-How then exists or in such other format as AMAG may reasonably request (including by download of digital files to a secure website or e-room designated and controlled by AMAG). Further, Palatin shall make appropriate personnel available to AMAG at reasonable times and places and upon reasonable prior notice for the purpose of assisting AMAG to understand and use the Palatin Technology in connection with AMAG’s Development, Manufacture, Commercialization and use of Compounds and Products.
Continuing Disclosure and Knowledge Transfer. On a ***, or more frequently at the reasonable request of a Party during the Term, each Party shall provide the JDC a written summary of all Know-How and Patent Rights that it develops to the extent such Know-How and/or Patent Rights are or are to be licensed or assigned to the other Party. *** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission.
Continuing Disclosure and Knowledge Transfer. On a ***, or more frequently at the reasonable request of a Party during the Term, each Party shall provide the JDC a written summary of all Know-How and Patent Rights that it develops to the extent such Know-How and/or Patent Rights are or are to be licensed or assigned to the other Party. *** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. Execution Version During the Term, each Party shall make appropriate personnel available to the other Party at reasonable times and places and upon reasonable prior notice for the purpose of assisting the other Party to understand and use such Know-How and Patent Rights.
Continuing Disclosure and Knowledge Transfer. On a [***] basis, or more frequently at the reasonable request of Pfizer during the Development Term, Valneva, to the extent not previously provided to Pfizer, will provide to Pfizer a written summary of all Valneva Technology that is licensed or developed by Valneva or that otherwise comes into the Control of Valneva that relates to the Development of any Vaccine, antibody, or Product, alone or in combination, for Lyme disease. Further, Valneva will make appropriate personnel (directly, or through an Affiliate) available to Pfizer at reasonable times and places in a way that does not require Valneva to form a permanent establishment in the United States of America for US tax purposes and upon reasonable prior notice for the purpose of assisting Pfizer to understand and use the Valneva Technology in connection with Pfizer’s Development, Manufacture, Commercialization and use of Vaccines and Products for Lyme Disease. [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) CUSTOMARILY AND ACTUALLY TREATED BY THE REGISTRANT AS PRIVATE OR CONFIDENTIAL.
Continuing Disclosure and Knowledge Transfer. On a Calendar Quarter basis, or more frequently at the reasonable request of Fosun during the Term, Palatin shall disclose to Fosun any Palatin Know-How developed or acquired by Palatin since Palatin’s most recent disclosure, but only to the extent the same is Controlled by Palatin. Such disclosure shall be in either the format in which such Palatin Know-How then exists or in such other format as Fosun may reasonably request (including by download of digital files to a secure website or e-room designated by Fosun). Further, Palatin shall make appropriate personnel available to Fosun at reasonable times and upon reasonable prior notice for the purpose of assisting Fosun to understand and use the Palatin Technology in connection with Fosun’s Development, Manufacture, Commercialization and use of Compounds and Products.
